OS Therapies Announces Q2 2026 Results and Regulatory Update
OSTX OS Therapies Inc
$1.62 +1.25%
View chart & analysis → 
- 1OS Therapies (OSTX) reported Q2 results for the period ended June 30, 2026, and provided an update on OST-HER2 regulatory progress
- 2Net operating loss of $8.576 million, or $0.20 per share; VAT refunds receivable exceed $3 million, with at least $4.2 million in Q3 R&D tax credits expected to be recognized
- 3Plans to pursue FDA accelerated approval BLA and UK/EU CMAA submissions in H2 for OST-HER2 in completely resected pulmonary metastatic osteosarcoma
This 3-line summary is compiled from the report below.
Newsfile Corp. +1 View original ↗
오늘의 AI 픽 5종목, 무료로 전부 공개합니다숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다